[go: up one dir, main page]

CN116406272A - Dna-pk选择性抑制剂及其制备方法和用途 - Google Patents

Dna-pk选择性抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN116406272A
CN116406272A CN202180061261.2A CN202180061261A CN116406272A CN 116406272 A CN116406272 A CN 116406272A CN 202180061261 A CN202180061261 A CN 202180061261A CN 116406272 A CN116406272 A CN 116406272A
Authority
CN
China
Prior art keywords
alkyl
membered
methyl
dihydro
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180061261.2A
Other languages
English (en)
Chinese (zh)
Inventor
陈曦
侯登
陈坤成
雷永珂
任仁
闵汪洋
刘志华
刘希杰
张凯
孙永亮
路畅
张苗
孙颖慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010708897.9A external-priority patent/CN113956272A/zh
Priority claimed from CN202010998179.XA external-priority patent/CN114195805A/zh
Priority claimed from CN202011298735.9A external-priority patent/CN114573584A/zh
Priority claimed from CN202011424931.6A external-priority patent/CN114605414A/zh
Priority claimed from CN202110181140.3A external-priority patent/CN114907384A/zh
Priority claimed from CN202110617681.6A external-priority patent/CN115433206A/zh
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Publication of CN116406272A publication Critical patent/CN116406272A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180061261.2A 2020-07-20 2021-07-20 Dna-pk选择性抑制剂及其制备方法和用途 Pending CN116406272A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CN2020107088979 2020-07-20
CN202010708897.9A CN113956272A (zh) 2020-07-20 2020-07-20 Dna-pk选择性抑制剂及其制备方法和用途
CN202010998179.XA CN114195805A (zh) 2020-09-18 2020-09-18 Dna-pk选择性抑制剂及其制备方法和用途
CN202010998179X 2020-09-18
CN2020112987359 2020-11-18
CN202011298735.9A CN114573584A (zh) 2020-11-18 2020-11-18 Dna-pk选择性抑制剂及其制备方法和用途
CN2020114249316 2020-12-08
CN202011424931.6A CN114605414A (zh) 2020-12-08 2020-12-08 Dna-pk选择性抑制剂及其制备方法和用途
CN202110181140.3A CN114907384A (zh) 2021-02-09 2021-02-09 Dna-pk选择性抑制剂及其制备方法和用途
CN2021101811403 2021-02-09
CN202110617681.6A CN115433206A (zh) 2021-06-03 2021-06-03 Dna-pk选择性抑制剂及其制备方法和用途
CN2021106176816 2021-06-03
PCT/CN2021/107304 WO2022017368A1 (fr) 2020-07-20 2021-07-20 Inhibiteur sélectif de dna-pk, son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
CN116406272A true CN116406272A (zh) 2023-07-07

Family

ID=79728958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180061261.2A Pending CN116406272A (zh) 2020-07-20 2021-07-20 Dna-pk选择性抑制剂及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN116406272A (fr)
WO (1) WO2022017368A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493471A (zh) * 2020-04-03 2021-10-12 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020385513A1 (en) * 2019-11-22 2022-07-14 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors
IL293318A (en) * 2019-11-25 2022-07-01 Medshine Discovery Inc Pyrimidoimidazole compounds used as dna-pk inhibitors
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
WO2023036156A1 (fr) * 2021-09-07 2023-03-16 首药控股(北京)股份有限公司 Inhibiteur sélectif de l'adn-pk, son procédé de préparation et son utilisation
WO2025049253A1 (fr) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Inhibiteurs à base de cycle ponté de protéine kinase dépendante de l'adn et compositions et application dans l'édition génique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114999A1 (fr) * 2016-12-20 2018-06-28 Astrazeneca Ab Composés amino-triazolopyridine et leur utilisation dans le traitement du cancer
WO2019238929A1 (fr) * 2018-06-15 2019-12-19 Astrazeneca Ab Composés de purinone et leur utilisation dans le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020385513A1 (en) * 2019-11-22 2022-07-14 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as DNA-PK inhibitors
IL293318A (en) * 2019-11-25 2022-07-01 Medshine Discovery Inc Pyrimidoimidazole compounds used as dna-pk inhibitors
WO2021136462A1 (fr) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 Dérivés furane et leur application en médecine
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
JP7428806B2 (ja) * 2019-12-31 2024-02-06 成都百裕制薬股▲ふん▼有限公司 プリン誘導体および医薬におけるその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114999A1 (fr) * 2016-12-20 2018-06-28 Astrazeneca Ab Composés amino-triazolopyridine et leur utilisation dans le traitement du cancer
WO2019238929A1 (fr) * 2018-06-15 2019-12-19 Astrazeneca Ab Composés de purinone et leur utilisation dans le traitement du cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493471A (zh) * 2020-04-03 2021-10-12 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
CN116917288A (zh) * 2021-03-22 2023-10-20 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途

Also Published As

Publication number Publication date
WO2022017368A1 (fr) 2022-01-27

Similar Documents

Publication Publication Date Title
CN116406272A (zh) Dna-pk选择性抑制剂及其制备方法和用途
CN113614087B (zh) Wee1抑制剂及其制备和用途
ES2619125T3 (es) Compuestos heterocíclicos fusionados como inhibidores de proteína cinasa
TWI893378B (zh) 三環雜環衍生物，其組合物和應用
JP6816287B2 (ja) ピリジン並びに５員芳香環系化合物、その製造方法及び使用
AU2017364807B2 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
AU2020410470A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN112584898B (zh) P2x3受体拮抗剂
KR20210131369A (ko) Fgfr4 키나아제 억제제 및 이의 제조 방법과 용도
WO2023036156A1 (fr) Inhibiteur sélectif de l'adn-pk, son procédé de préparation et son utilisation
EP4558502A1 (fr) Composés d'aza-quinazoline et procédés d'utilisation
WO2024015412A1 (fr) Dérivés de tétrahydronaphtalène en tant que agents de dégradation du récepteur des oestrogènes
TW202229248A (zh) Hsd17b13抑制劑及其用途
WO2024020380A1 (fr) Composés de quinazoline et procédés d'utilisation
CN113956272A (zh) Dna-pk选择性抑制剂及其制备方法和用途
WO2024054512A1 (fr) Modulateurs de akt1
CN117425660A (zh) 一种芳杂环类化合物及其中间体、药物组合物和用途
CN114605414A (zh) Dna-pk选择性抑制剂及其制备方法和用途
CN114195805A (zh) Dna-pk选择性抑制剂及其制备方法和用途
CN114573584A (zh) Dna-pk选择性抑制剂及其制备方法和用途
WO2024107565A1 (fr) Modulateurs de akt1
CN120051471A (zh) 一种新型杂环化合物
CN111848598B (zh) 一种含杂环的化合物、其应用及含其的组合物
CN114907384A (zh) Dna-pk选择性抑制剂及其制备方法和用途
WO2025128834A1 (fr) Modulateurs d'akt1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination